Author + information
- Received August 7, 2019
- Revision received October 27, 2019
- Accepted November 11, 2019
- Published online January 27, 2020.
- Seung-Pyo Lee, MD, PhDa,
- Hoon-Young Suh, MDb,
- Sohyun Park, MDb,
- Sera Oh, BSb,
- Soon-Gu Kwak, MDa,
- Hyue-Mee Kim, MDa,c,
- Youngil Koh, MD, PhDd,
- Jun-Bean Park, MD, PhDa,
- Hyung-Kwan Kim, MD, PhDa,
- Hyun-Jai Cho, MD, PhDa,
- Yong-Jin Kim, MD, PhDa,
- Inho Kim, MD, PhDd,
- Sung-Soo Yoon, MD, PhDd,
- Jeong-Wook Seo, MD, PhDe,
- Jin-Chul Paeng, MD, PhDb and
- Dae-Won Sohn, MD, PhDa,∗ ()
- aDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- bDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- cDepartment of Internal Medicine, Mediplex Sejong Hospital, Incheon, Republic of Korea
- dDivision of Hemato-oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- eDepartment of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
- ↵∗Address for correspondence:
Dr. Dae-Won Sohn, Cardiovascular Center, Seoul National University Hospital and Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongro-gu, Seoul 03080, Republic of Korea.
Background It remains unknown whether the noninvasive evaluation of the degree of amyloid deposition in the myocardium can predict the prognosis of patients with light chain (AL) cardiac amyloidosis.
Objectives The purpose of this study was to demonstrate that 11C-Pittsburgh B compound positron emission tomography (11C-PiB PET) is useful for prognostication of AL cardiac amyloidosis by noninvasively imaging the myocardial AL amyloid deposition.
Methods This study consecutively enrolled 41 chemotherapy-naïve AL cardiac amyloidosis patients. The amyloid deposit was quantitatively assessed with amyloid P immunohistochemistry in endomyocardial biopsy specimens and was compared with the degree of myocardial 11C-PiB uptake on PET. The primary endpoint was a composite of all-cause death, heart transplantation, and acute decompensated heart failure.
Results The degree of myocardial 11C-PiB PET uptake was significantly higher in the cardiac amyloidosis patients compared with normal subjects and correlated well with the degree of amyloid deposit on histology (R2 = 0.343, p < 0.001). During follow-up (median: 423 days, interquartile range: 93 to 1,222 days), 24 patients experienced the primary endpoint. When the cardiac amyloidosis patients were divided into tertiles by the degree of myocardial 11C-PiB PET uptake, patients with the highest PiB uptake experienced the worst clinical event-free survival (log-rank p = 0.014). The degree of myocardial PiB PET uptake was a significant predictor of clinical outcome on multivariate Cox regression analysis (adjusted hazard ratio: 1.185; 95% confidence interval: 1.054 to 1.332; p = 0.005).
Conclusions These proof-of-concept results show that noninvasive evaluation of myocardial amyloid load by 11C-PiB PET reflects the degree of amyloid deposit and is an independent predictor of clinical outcome in AL cardiac amyloidosis patients.
This work was supported by a grant from the Korean Health Technology R&D Project (HI15C0399), Ministry of Health, Welfare & Family Affairs, South Korea, and by the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science and ICT) (No. 2019R1A2C2084099). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 7, 2019.
- Revision received October 27, 2019.
- Accepted November 11, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.